These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32352244)

  • 1. Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
    Welt A; Wiesweg M; Theurer S; Abenhardt W; Groschek M; Müller L; Schröder J; Tewes M; Chiabudini M; Potthoff K; Bankfalvi A; Marschner N; Schuler M; Breitenbücher F
    Cancer Med; 2020 Jul; 9(13):4527-4539. PubMed ID: 32352244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
    Loibl S; de la Pena L; Nekljudova V; Zardavas D; Michiels S; Denkert C; Rezai M; Bermejo B; Untch M; Lee SC; Turri S; Urban P; Kümmel S; Steger G; Gombos A; Lux M; Piccart MJ; Von Minckwitz G; Baselga J; Loi S
    Eur J Cancer; 2017 Nov; 85():133-145. PubMed ID: 28923573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
    Martín M; Chan A; Dirix L; O'Shaughnessy J; Hegg R; Manikhas A; Shtivelband M; Krivorotko P; Batista López N; Campone M; Ruiz Borrego M; Khan QJ; Beck JT; Ramos Vázquez M; Urban P; Goteti S; Di Tomaso E; Massacesi C; Delaloge S
    Ann Oncol; 2017 Feb; 28(2):313-320. PubMed ID: 27803006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
    Garrido-Castro AC; Saura C; Barroso-Sousa R; Guo H; Ciruelos E; Bermejo B; Gavilá J; Serra V; Prat A; Paré L; Céliz P; Villagrasa P; Li Y; Savoie J; Xu Z; Arteaga CL; Krop IE; Solit DB; Mills GB; Cantley LC; Winer EP; Lin NU; Rodon J
    Breast Cancer Res; 2020 Nov; 22(1):120. PubMed ID: 33138866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Mayer IA; Abramson VG; Isakoff SJ; Forero A; Balko JM; Kuba MG; Sanders ME; Yap JT; Van den Abbeele AD; Li Y; Cantley LC; Winer E; Arteaga CL
    J Clin Oncol; 2014 Apr; 32(12):1202-9. PubMed ID: 24663045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
    Pistilli B; Pluard T; Urruticoechea A; Farci D; Kong A; Bachelot T; Chan S; Han HS; Jerusalem G; Urban P; Robinson D; Mouhaër SL; Tomaso ED; Massacesi C; Saura C
    Breast Cancer Res Treat; 2018 Apr; 168(2):357-364. PubMed ID: 29198055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
    Vuylsteke P; Huizing M; Petrakova K; Roylance R; Laing R; Chan S; Abell F; Gendreau S; Rooney I; Apt D; Zhou J; Singel S; Fehrenbacher L
    Ann Oncol; 2016 Nov; 27(11):2059-2066. PubMed ID: 27573562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
    Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
    JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
    Turner N; Dent RA; O'Shaughnessy J; Kim SB; Isakoff SJ; Barrios C; Saji S; Bondarenko I; Nowecki Z; Lian Q; Reilly SJ; Hinton H; Wongchenko MJ; Kovic B; Mani A; Oliveira M
    Breast Cancer Res Treat; 2022 Feb; 191(3):565-576. PubMed ID: 34860318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Luo J; Naughton M; Ademuyiwa F; Suresh R; Griffith M; Griffith OL; Skidmore ZL; Spies NC; Ramu A; Trani L; Pluard T; Nagaraj G; Thomas S; Guo Z; Hoog J; Han J; Mardis E; Lockhart C; Ellis MJ
    Clin Cancer Res; 2016 Apr; 22(7):1583-91. PubMed ID: 26563128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
    Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
    Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
    Rodon J; Braña I; Siu LL; De Jonge MJ; Homji N; Mills D; Di Tomaso E; Sarr C; Trandafir L; Massacesi C; Eskens F; Bendell JC
    Invest New Drugs; 2014 Aug; 32(4):670-81. PubMed ID: 24652201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
    Dent S; Cortés J; Im YH; Diéras V; Harbeck N; Krop IE; Wilson TR; Cui N; Schimmoller F; Hsu JY; He J; De Laurentiis M; Sousa S; Drullinsky P; Jacot W
    Ann Oncol; 2021 Feb; 32(2):197-207. PubMed ID: 33186740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
    Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
    Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
    Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
    Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
    Campone M; Im SA; Iwata H; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Cortés J; De Laurentiis M; Arteaga CL; Jiang Z; Jonat W; Le Mouhaër S; Sankaran B; Bourdeau L; El-Hashimy M; Sellami D; Baselga J
    Eur J Cancer; 2018 Nov; 103():147-154. PubMed ID: 30241001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.